Acz885d (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 108 | TNF受容体関連周期性症候群 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2010-020061-24-IT (EUCTR) | 20/09/2010 | 05/07/2010 | An open-label, multicenter, efficacy and safety study of 4-month canakinumab treatment with 6-month follow-up in patients with active recurrent or chronic TNF-receptor associated periodic syndrome (TRAPS) - ND | An open-label, multicenter, efficacy and safety study of 4-month canakinumab treatment with 6-month follow-up in patients with active recurrent or chronic TNF-receptor associated periodic syndrome (TRAPS) - ND | Active recurrent or chronic TNF-receptor associated periodic syndrome (TRAPS) MedDRA version: 12.1;Level: LLT;Classification code 10034533;Term: Periodic fever | Product Name: canakinumab Product Code: ACZ885D INN or Proposed INN: Canakinumab | NOVARTIS FARMA | NULL | Not Recruiting | Female: yes Male: yes | 50 | Ireland;United Kingdom;Italy |